journal
MENU ▼
Read by QxMD icon Read
search

Current Hematologic Malignancy Reports

journal
https://www.readbyqxmd.com/read/29105027/rare-cancers-and-social-media-analysis-of-twitter-metrics-in-the-first-2%C3%A2-years-of-a-rare-disease-community-for-myeloproliferative-neoplasms-on-social-media-mpnsm
#1
REVIEW
Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Jean-Jacques Kiladjian, Ruben Mesa, Michael A Thompson
PURPOSE OF REVIEW: The use of social media has now become a standard 13 means of communication for many individuals worldwide. 14 The use of one specific form of social media, Twitter, has 15 increased among healthcare providers, both as a means of 16 information gathering and as a conduit for original content 17 creation. Recently, major efforts by users have been put for- 18 ward to help streamline the unprecedented amount of infor- 19 mation that can be found on Twitter. These efforts have led to 20 the creation of diseasespecific hashtag (#) medical communi- 21 ties and have greatly enhanced the ability to understand and 22 better categorize the available data on Twitter...
November 6, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29098609/methods-of-detection-of-measurable-residual-disease-in-aml
#2
REVIEW
Yi Zhou, Brent L Wood
The presence of measurable ("minimal") residual disease (MRD) after induction and/or consolidation chemotherapy is a significant risk factor for relapse in patients with acute myeloid leukemia (AML). In recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRD(Negative) as a separate category of treatment response. This recommendation represents a major milestone in the integration of AML MRD testing in standard clinical practice. This review article summarizes the methodologies employed in AML MRD detection and their application in clinical studies that provide evidence supporting the clinical utility of AML MRD testing...
November 2, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29098608/novel-therapies-for-myelofibrosis
#3
REVIEW
Kristen Pettit, Olatoyosi Odenike
PURPOSE OF REVIEW: The purpose of the review was to provide a contemporary update of novel agents and targets under investigation in myelofibrosis in the Janus kinase (JAK) inhibitor era. RECENT FINDINGS: Myelofibrosis (MF) is a clonal stem cell disease characterized by marrow fibrosis and a heterogeneous disease phenotype with a variable degree of splenomegaly, cytopenias, and constitutional symptoms that significantly impact quality of life and survival. Overactive JAK/STAT signaling is a hallmark of MF...
November 2, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29076056/using-social-media-at-national-meetings-in-hematology-optimal-use-tips-strategies-and-limitations
#4
REVIEW
Aaron C Logan
Social media has become an important tool for physicians and scientists to rapidly share information with colleagues around the world. Use of social media outlets-in particular, Twitter-has risen rapidly in recent years, and it is now customary for national hematology meetings to have thousands of participants who share photographs and textual summaries of data presentations, as well as personal insights and commentary, with virtual audiences. These messages, or "tweets," can be specifically followed using a hashtag ontology which arose organically over the past several years in the context of medical meetings...
October 26, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064027/social-media-in-hematology-in-2017-dystopia-utopia-or-somewhere-in-between
#5
REVIEW
Aaron T Gerds, Teresa Chan
PURPOSE OF REVIEW: Social media is becoming a crucial part of our society. While the field of medicine has lagged behind in adopting and harnessing these platforms, we are now starting to see a surge in social media usage for medical education and scientific communication (e.g., knowledge translation, research collaboration, discussion, and discourse). Over the course of this review, we aim to update the reader on the way in which Twitter and other social media platforms may be used in hematology for research ideas, collaboration, and scholarly activity...
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064026/models-of-prognostication-in-chronic-myelomonocytic-leukemia
#6
REVIEW
Francesco Onida
PURPOSE OF REVIEW: Within the group of the myelodysplastic/myeloproliferative overlap neoplasms of the adult age, chronic myelomonocytic leukemia (CMML) is characterized by an extremely variable clinical course. This review aims to cover over the years main advancements in the identification of CMML clinical and biological features associated to survival outcomes and the consequent development of prognostic tools for individual patient treatment decision making. RECENT FINDINGS: According to the last WHO classification of myeloid neoplasms, three subgroups of patients may be recognized on the base of percentage of blasts in marrow and in peripheral blood (CMML-0, CMML-1, and CMML-2), with corresponding decreasing life-expectations...
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064025/analysis-of-first-year-twitter-metrics-of-a-rare-disease-community-for-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-on-social-media-bpdcn
#7
REVIEW
Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Michael A Thompson, Andrew A Lane
PURPOSE OF REVIEW: The use of Twitter, one of the most commonly engaged social media platforms in the world, is increasing among the general public. Notably, this trend has also been observed among those involved in the healthcare field. With its ability to readily connect diverse groups of stakeholders in a given area of interest, Twitter has become a focal point for those involved in increasing awareness and information exchange in orphan disease fields. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with generally poor long-term outcomes for adult patients and no standard therapeutic guidelines...
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064024/measurement-of-residual-disease-in-acute-myeloid-leukemia
#8
REVIEW
Rahul S Vedula, R Coleman Lindsley
PURPOSE OF REVIEW: Assessment of measurable residual disease (MRD) after treatment can identify patients with acute myeloid leukemia (AML) that are at high risk of poor outcomes. However, there is no consensus yet regarding a standardized approach to measuring MRD that is most clinically meaningful. We review multiparameter flow cytometry (MFC) and reverse transcriptase polymerase chain reaction (RT-PCR), and discuss a framework for assessing remission MRD using next-generation sequencing (NGS)...
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064023/diagnostic-and-prognostic-utility-of-fluorescence-in-situ-hybridization-fish-analysis-in-acute-myeloid-leukemia
#9
REVIEW
Patrick R Gonzales, Fady M Mikhail
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a hematologic neoplasia consisting of incompletely differentiated hematopoietic cells of the myeloid lineage that proliferate in the bone marrow, blood, and/or other tissues. Clinical implementation of fluorescence in situ hybridization (FISH) in cytogenetic laboratories allows for high-resolution analysis of recurrent structural chromosomal rearrangements specific to AML, especially in AML with normal karyotypes, which comprises approximately 33-50% of AML-positive specimens...
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064022/novel-pathways-and-potential-therapeutic-strategies-for-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-cd123-and-beyond
#10
REVIEW
Naveen Pemmaraju
No abstract text is available yet for this article.
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29064021/targeting-idh1-and-idh2-mutations-in-acute-myeloid-leukemia
#11
REVIEW
Brittany Knick Ragon, Courtney D DiNardo
PURPOSE OF REVIEW: Over the past decade, the pathogenic role of mutations in isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML, has been defined, allowing for the development of specific therapeutic strategies for IDH-mutant AML. In this review, the landscape and progress of targeted therapeutics aimed at IDH mutations in AML and related myeloid malignancies will be described. RECENT FINDINGS: Since 2013, several mutant IDH-targeted inhibitors have been developed, and nearly a dozen clinical trials have opened specifically for IDH-mutant hematologic malignancies...
October 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29039115/genome-editing-technologies-in-adoptive-t-cell-immunotherapy-for-cancer
#12
REVIEW
Nathan Singh, Junwei Shi, Carl H June, Marco Ruella
PURPOSE OF REVIEW: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. RECENT FINDINGS: Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies...
October 16, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29032412/prognostication-and-initiation-of-therapy-in-polycythemia-vera-do-we-have-it-right
#13
REVIEW
Brady L Stein, Srdan Verstovsek
ᅟ.
October 14, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29027628/the-prognostic-significance-of-measurable-minimal-residual-disease-in-acute-myeloid-leukemia
#14
REVIEW
Francesco Buccisano, Christopher S Hourigan, Roland B Walter
PURPOSE OF REVIEW: The purpose of this review was to evaluate recent literature on detection methodologies for, and prognostic significance of, measurable ("minimal") residual disease (MRD) in acute myeloid leukemia (AML). RECENT FINDINGS: There is no "one-fits-all" approach to MRD testing in AML. Most exploited to date are methods relying on immunophenotypic aberrancies (identified via multiparameter flow cytometry) or genetic abnormalities (identified via PCR-based assays)...
October 13, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29027642/familial-mpn-predisposition
#15
REVIEW
Tsewang Tashi, Sabina Swierczek, Josef T Prchal
Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been long speculated, but has not been clearly defined to date. Genome-wide association studies in family clusters of MPN have identified a number of genetic variants that are associated with increased germline risk for developing clonal MPN...
October 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28983816/recent-progress-in-chronic-neutrophilic-leukemia-and-atypical-chronic-myeloid-leukemia
#16
REVIEW
Kim-Hien T Dao, Jeffrey W Tyner, Jason Gotlib
PURPOSE OF REVIEW: We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients. RECENT FINDINGS: Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia...
October 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28983777/therapy-for-chronic-myelomonocytic-leukemia-in-a-new-era
#17
REVIEW
Tamara K Moyo, Michael R Savona
Chronic myelomonocytic leukemia (CMML) is a myeloid malignancy which shares clinical and morphologic features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) and is classified by the WHO as an MDS/MPN. The defining feature of CMML is clonal hematopoiesis that results in peripheral monocytosis. The benefit of early treatment is currently unclear, and treatment may be held until the disease exhibits accelerated blast counts or the patient becomes symptomatic. Optimal treatments for CMML are not well defined...
October 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28948521/contemporary-use-of-interferon-therapy-in-the-myeloproliferative-neoplasms
#18
REVIEW
Charles Elliott Foucar, Brady Lee Stein
PURPOSE OF REVIEW: The purpose of this article is to review the current evidence behind interferon therapy in patients with myeloproliferative neoplasms. RECENT FINDINGS: Preliminary analysis suggests that interferon may be non-inferior to hydroxyurea in patients with polycythemia vera and essential thrombocytosis. Responses have been observed regardless of JAK2 mutational status, but the presence of non-JAK2 somatic mutations may negatively influence response rates...
October 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28948496/risk-factors-for-and-management-of-mpn-associated-bleeding-and-thrombosis
#19
REVIEW
Karlyn Martin
PURPOSE OF THE REVIEW: The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) are characterized by both thrombotic and bleeding complications. The purpose of this review is to describe the risk factors associated with bleeding and thrombosis in MPN, as well as to review prevention strategies and management of these complications. RECENT FINDINGS: Well-described risk factors for thrombotic complications include older age and history of prior thrombosis, along with traditional cardiovascular and venous thromboembolic risk factors...
October 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28948488/prognostication-in-philadelphia-chromosome-negative-myeloproliferative-neoplasms-a-review-of-the-recent-literature
#20
REVIEW
Amy Zhou, Amber Afzal, Stephen T Oh
PURPOSE OF REVIEW: The prognosis for patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) is highly variable. All Ph-negative MPNs carry an increased risk for thrombotic complications, bleeding, and leukemic transformation. Several clinical, biological, and molecular prognostic factors have been identified in recent years, which provide important information in guiding management of patients with Ph-negative MPNs. In this review, we critically evaluate the recent published literature and discuss important new developments in clinical and molecular factors that impact survival, disease transformation, and thrombosis in patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis...
October 2017: Current Hematologic Malignancy Reports
journal
journal
41232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"